Triptorelin
Triptorelin is a peptide, indexed here under Endocrine and immune signalling peptides.
Identity
| Field | Value |
|---|---|
| Classification | Peptide |
| Primary class | Endocrine and immune signalling peptides |
| CAS registry number | 57773-63-4[1] |
| PubChem CID | 25074470[1] |
| UniProt accession | Unknown No UniProt query was run in v1. |
| Molecular formula | C64H82N18O13[1] |
| Molecular weight | 1311.4 g/mol[1] |
| Amino-acid sequence | Unknown Not reported by the PubChem property set retrieved for this record; no sequence database query was run in v1. |
| Reported half-life | Unknown No pharmacokinetics source was retrieved in v1. PubChem does not carry half-life as a property, so this is recorded as not yet sourced rather than estimated. |
What the cited literature examines
Triptorelin is a synthetic analogue of gonadotropin-releasing hormone. The Drugs@FDA register returned approved applications under this generic name; those products are recorded in the regulatory status field and are not what this page describes. A 2003 BJU International paper compares triptorelin pamoate and leuprolide acetate in men with advanced prostate cancer, and a 1999 Journal of Clinical Endocrinology and Metabolism paper reports final height after long-term slow-release administration in central precocious puberty.
The retrieved records are otherwise reproductive medicine and oncology. 2000 Fertility and Sterility and Human Reproduction papers report a single dose to trigger ovulation in in vitro fertilisation, a 2001 Human Reproduction paper compares the GnRH antagonist ganirelix with a long protocol of triptorelin, 2002 and 2010 Fertility and Sterility papers compare it with dienogest and with letrozole in endometriosis, a 2011 JAMA paper and a 2012 Journal of Clinical Oncology paper report its use during chemotherapy to preserve ovarian function, and 2015 JAMA and 2016 Journal of Clinical Oncology papers report ovarian suppression and oestrogen levels in premenopausal women with breast cancer.
[3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13]Reported mechanism
A gonadotropin-releasing hormone agonist; the retrieved records report ovarian and testicular suppression after sustained administration and ovulation triggering after a single bolus.
[10, 6]Stated in the titles of the cited 2011 JAMA and 2000 Human Reproduction papers.
Targets named in the cited records: GnRH receptor.
FDA application register
A query of the FDA Drugs@FDA application register on 2026-10-09 returned 4 application record(s) for this compound name (including NDA021288, NDA020715, NDA208956, NDA022437, marketed as TRELSTAR, TRIPTODUR KIT). Material supplied as a research chemical is not the subject of those applications and is not an FDA-approved product.[2]
Scope statement: this records the result of a single automated query against the openFDA drugsfda endpoint on the stated date. It is not legal advice and is not a jurisdiction-by-jurisdiction legality assessment.
Retrieved 2026-10-09.
Amounts reported in the cited literature
Unknown. No retrieved record in this dataset states an amount, so none is shown. Where an amount is recorded it is what a named study reported administering in its own stated model, in the past tense, and is not a protocol.
No study-reported dose was taken from a source read in v1. Literature-reported values are only recorded where the retrieved citation metadata states the figure.
Adverse effects reported in the cited literature
Unknown. No retrieved record in this dataset reports an adverse effect for this compound, so no row is shown. Absence of a row records the absence of a retrieved report, nothing more.
No adverse-effect row was taken from a source read in v1. Rows are only recorded with the study model named and the reporting citation attached.
Other names
Triptorelin appears under these other names in the cited records or in common usage. Each one resolves to this page rather than to a separate page of its own.
- triptorelin pamoate
- Trelstar
- Decapeptyl
Where this page sits
Research records
Cited research records for Triptorelin, each with its identifier, the publication type it is indexed as, and the study model stated by its assigned subject headings.
Compounds indexed next to it
- Gonadorelin — Endocrine and immune signalling peptides
- Leuprolide — Endocrine and immune signalling peptides
Class page: Endocrine and immune signalling peptides. Full index: all indexed compounds.
Questions this page answers
What does the cited literature examine for Triptorelin?
Triptorelin is a synthetic analogue of gonadotropin-releasing hormone. The Drugs@FDA register returned approved applications under this generic name; those products are recorded in the regulatory status field and are not what this page describes.
Which class is Triptorelin indexed under?
Triptorelin is indexed under Endocrine and immune signalling peptides. This class groups peptides whose retrieved literature concerns endocrine or immune signalling outside the growth hormone axis.
What does the FDA application register show for Triptorelin?
A query of the FDA Drugs@FDA application register on 2026-10-09 returned 4 application record(s) for this compound name (including NDA021288, NDA020715, NDA208956, NDA022437, marketed as TRELSTAR, TRIPTODUR KIT). Material supplied as a research chemical is not the subject of those applications and is not an FDA-approved product.
Sources
- PubChem Compound Summary for CID 25074470, Triptorelin. PubChem, National Library of Medicine (2026). pubchem:25074470
- Drugs@FDA application register query for this compound, 4 application(s) returned: NDA021288, NDA020715, NDA208956, NDA022437. U.S. Food and Drug Administration, openFDA drugsfda endpoint (2026). fda:triptorelin
- Comparative efficacy of triptorelin pamoate and leuprolide acetate in men with advanced prostate cancer. BJU international (2003). pmid:12887472
- Final height after long-term treatment with triptorelin slow release for central precocious puberty: importance of statural growth after interruption of treatment. French study group of Decapeptyl in Precocious Puberty. The Journal of clinical endocrinology and metabolism (1999). pmid:10372696
- Prospective, randomized, controlled study of in vitro fertilization-embryo transfer with a single dose of a luteinizing hormone-releasing hormone (LH-RH) antagonist (cetrorelix) or a depot formula of an LH-RH agonist (triptorelin). Fertility and sterility (2000). pmid:10685535
- Use of a single bolus of GnRH agonist triptorelin to trigger ovulation after GnRH antagonist ganirelix treatment in women undergoing ovarian stimulation for assisted reproduction, with special reference to the prevention of ovarian hyperstimulation syndrome: preliminary report: short communication. Human reproduction (Oxford, England) (2000). pmid:10966996
- Comparable clinical outcome using the GnRH antagonist ganirelix or a long protocol of the GnRH agonist triptorelin for the prevention of premature LH surges in women undergoing ovarian stimulation. Human reproduction (Oxford, England) (2001). pmid:11278211
- Dienogest is as effective as triptorelin in the treatment of endometriosis after laparoscopic surgery: results of a prospective, multicenter, randomized study. Fertility and sterility (2002). pmid:11937116
- A randomized, controlled clinical trial comparing the effects of aromatase inhibitor (letrozole) and gonadotropin-releasing hormone agonist (triptorelin) on uterine leiomyoma volume and hormonal status. Fertility and sterility (2010). pmid:19135657
- Effect of the gonadotropin-releasing hormone analogue triptorelin on the occurrence of chemotherapy-induced early menopause in premenopausal women with breast cancer: a randomized trial. JAMA (2011). pmid:21771987
- Randomized trial using gonadotropin-releasing hormone agonist triptorelin for the preservation of ovarian function during (neo)adjuvant chemotherapy for breast cancer. Journal of clinical oncology : official journal of the American Society of Clinical Oncology (2012). pmid:22231041
- Ovarian Suppression With Triptorelin During Adjuvant Breast Cancer Chemotherapy and Long-term Ovarian Function, Pregnancies, and Disease-Free Survival: A Randomized Clinical Trial. JAMA (2015). pmid:26720025
- Twelve-Month Estrogen Levels in Premenopausal Women With Hormone Receptor-Positive Breast Cancer Receiving Adjuvant Triptorelin Plus Exemestane or Tamoxifen in the Suppression of Ovarian Function Trial (SOFT): The SOFT-EST Substudy. Journal of clinical oncology : official journal of the American Society of Clinical Oncology (2016). pmid:26729437
On each stated value was matched to the record cited for it. That is record matching, not an appraisal of the research. Compiled and checked by: Peptide Monographs editorial desk. No qualified clinical reviewer.